Fig. 1: β-Glucan treatment induces disease tolerance against IAV.
From: β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus
a, Mice were infected with IAV at day 7 post-β-glucan treatment i.p. b,c, Weight loss (b) and survival (c) monitored over time (n = 10) of mice infected with a lethal dose of IAV (120 p.f.u.). d, Viral burden quantified at several time points post-IAV infection with a lethal dose (n = 5). e, Viral burden quantified at several time points post-IAV infection with a sublethal dose (50 p.f.u.; n = 5). f, Representative micrographs of lung histology from β-glucan (7 d)-treated mice stained with H&E day 6 post-IAV infection.Scale bar, 200 μm. g, Lung histology scoring at day 6 post-IAV infection after β-glucan treatment (n = 5). h–k, Mice were infected with a sublethal dose of IAV at day 7 post-β-glucan, followed at day 6 post-IAV infection: quantification of endothelial permeability (h), pulmonary edema (i), BAL protein (j) and BAL erythrocytes (k) (n = 5). Data are represented as mean ± s.e.m. Data were analyzed using two-tailed, unpaired Student’s t-test (g) or two-way ANOVA followed by Šidák’s multiple-comparison tests (b and h–k). Survival was monitored by a log(rank) test (c). *P < 0.05, ***P < 0.001, ****P < 0.0001. i.n., intranasally; uninf., uninfected. Illustrations in a created using BioRender.com.
